A live webcast of the presentation will be available on the company's website at www.mateon.com in "Events & Presentations" under the "Investors & News" tab. A replay of the webcast will be available approximately one hour following the completion of the live event.
At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.
Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.
CONTACTS Investors: firstname.lastname@example.org 650-635-7000 Media:
JPA Health Communications Nic DiBellanic@jpa.com 617-945-5183
News Provided by Acquire Media